AstraZeneca

AZN

Capitalización de mercado USD 257 mil M

AZN, RHHBY, PBYI and OLMA offer exposure to breast cancer drug sales growth, expanded treatment approvals and clinical milestones that could shape prospects.

Astrazeneca (AZN) closed the most recent trading day at $166.68, moving +2.87% from the previous trading session.

RBC Capital Markets has maintained its 'outperform' rating on AstraZeneca PLC (LSE:AZN, NYSE:AZN), the FTSE 100 pharmaceutical group, with a 14,500p target price, expecting a quiet third quarter before results on Friday 30 October. It forecasts third-quarter revenue of $16.3 billion, 1.8% above the consensus estimate of $16.0 billion, and core earnings per share (EPS) of $2.61, 0.8% ahead of the $2.59 consensus.

AstraZeneca PLC (AZN) Presents at American Society for Bone and Mineral Research (ASBMR) 2026 Annual Meeting Transcript

Astrazeneca NYSE: AZN presented Phase III data for efzimfotase alfa, an investigational enzyme replacement therapy for hypophosphatasia (HPP), at the American Society for Bone and Mineral Research annual meeting in Boston. The company said the therapy showed improvements in several measures of function, pain and fatigue in adolescents and adults, although the HICKORY trial did not meet its primary endpoint.

Citi has maintained its 'buy' rating on AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) with a target price of £186, arguing that detailed trial data for its rare disease drug efzimfotase alfa support a peak sales scenario almost double its current base case if the therapy secures broad adult approval in the US. The data, presented at the American Society for Bone and Mineral Research meeting, came from the Phase III HICKORY trial of the enzyme replacement therapy in patients with hypophosphatasia, a rare inherited bone disorder.

SALT LAKE CITY and BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine and SOPHiA GENETICS (NASDAQ: SOPH) today announce a collaboration to advance new prostate cancer-specific genomic instability score (PrGIS) technology to support precision oncology approaches with AstraZeneca (LSE/STO/NYSE: AZN). PrGIS is a novel biomarker signature designed to assess chromosomal instability associated with homologous recombination deficiency (HRD) in prostate cancer patients.

BOSTON, Oct. 8, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH) and Myriad Genetics, Inc., (NASDAQ: MYGN) today announce a collaboration to advance new prostate cancer-specific genomic instability score (PrGIS) technology to support precision oncology approaches with AstraZeneca (LSE/STO/NYSE: AZN). PrGIS is a novel biomarker signature designed to assess chromosomal instability associated with homologous recombination deficiency (HRD) in prostate cancer patients.

Jefferies maintained a 'buy' rating on AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the biopharmaceutical company, with a 17,500p price target, representing 46% potential upside from its 11,958p share price. The broker expects AstraZeneca to report third-quarter revenue about 1% ahead of the Visible Alpha consensus and core earnings before interest and tax at 3% above expectations.

In the latest trading session, Astrazeneca (AZN) closed at $158.61, marking a +1.33% move from the previous day.